India's pharma industry floods market with generic semaglutide.
India’s pharmaceutical market is set for disruption as over 40 domestic companies launch generic versions of semaglutide, the active ingredient in Novo Nordisk’s blockbuster drugs Ozempic and Wegovy. This surge in supply, driven by the expiration of patents, promises to drastically cut prices and expand access to this weight loss and diabetes medication.
The entry of Indian firms could significantly alter the global market dynamics for semaglutide. While Novo Nordisk currently dominates with its branded products, the availability of affordable generics may shift market share and pricing strategies. The move is expected to address pressing health challenges in India, where diabetes and obesity rates are rapidly increasing.
However, the widespread availability of semaglutide also raises concerns about potential misuse and the need for robust regulatory oversight. Experts emphasize the importance of ensuring proper medical supervision and preventing the drug from being used purely for cosmetic weight loss purposes.
This development underscores the growing capabilities of Indian pharmaceutical companies in producing generic versions of complex drugs. It also highlights the increasing competition in the global market for weight management and diabetes treatments, potentially impacting the strategies of major players like Novo Nordisk and Eli Lilly.
About the Author
